Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to email their news releases to BioNJ.
February 14
Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug
Merck to Present at the Leerink Swann 2012 Global Healthcare Conference
Presentation of the Fourth Quarter and Full Year 2011 Report
February 13
Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients with Myelodysplastic Syndromes
February 10
Amicus Therapeutics to Present at Leerink Swann 2012 Global Healthcare Conference
Soligenix Announces Results from its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
February 9
Advaxis to Present at the 14th Annual BIO CEO & Investor Conference
Aegerion Pharmaceuticals Announces Webcast of Investor Presentations at Upcoming Conferences
Amicus Therapeutics Presents Preclinical Studies of Chaperone AT3375 for Gaucher Disease
Gilead Sciences to Present at Two Upcoming Investor Conferences
February 8
Immunomedics Announces Second-Quarter Fiscal 2012 Results and Clinical Program Developments
Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
Bristol-Myers Squibb to Present at Leerink Swann 2012 Global Healthcare Conference
February 7
Merck Announces Top-Line Results of TRA-2P Study of Vorapaxar
Amicus Therapeutics Awarded Grant from Muscular Dystrophy Association for Pompe Disease Program
Lexicon Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference
Unigene to Present at the 14th Annual Bio CEO & Investor Conference
NPS Pharmaceuticals to Present at Upcoming Conferences
Cyclacel to Present at Upcoming Investor Conferences
February 3
SAFE-BioPharma Standard to Be Highlighted at Molecular TriCon
February 2
Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
Photocure’s Partner Ipsen Announces 4Q 11 Hexvix Sales in Germany and Italy
Gilead Sciences Announces Fourth-Quarter and Full-Year 2011 Financial Results
February 1
Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
Soligenix Announces 1 for 20 Reverse-Split of Its Common Stock
Immunomedics Awarded Broad Patent for Anti-Cd20 and Anti-Cd22 Combination Therapy
January 26
Celgene to Acquire Avila Therapeutics
Celgene Reports Record Fourth-Quarter and Full-Year 2011 Operating and Financial Results
Celator Pharmaceuticals Receives EMA Orphan Drug Status for CPX-351 in Acute Myeloid Leukemia
Acsis, Inc. Appoints Paul Allen to Board of Directors
Advaxis CEO Tom Moore Interviewed by OneMedPlace Regarding Preliminary Data
January 24
Bristol-Myers Squibb Names Gerald L. Storch to Board of Directors
January 23
Celgene Corporation Elects Dr. Richard W. Barker to Its Board of Directors
Amicus Therapeutics Appoints Bradley L. Campbell as Chief Business Officer
The Medicines Company Settles Angiomax (Bivalirudin) Patent Litigations with App Pharmaceuticals
NovaDel Announces Termination of License Agreements for Ondansetron Oral Spray Product
January 19
Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients
EDA Approves Investment in Venture Fund, Announces Incentive Recipients
Three Major IT Trends Will Shape Life Sciences in 2012
January 18
Soligenix Demonstrates Robust Stability Results with its SGX204 Anthrax Vaccine
Celldex Therapeutics to Host Research and Development Day Highlighting Oncology Pipeline
Virtual Collaboration and Training Comes to Life Sciences Organizations
NovaDel Continuing to Explore Strategic Alternatives
Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301